

---

# UCSF DERMATOLOGY GRAND ROUNDS – JUNE 2025

---

**Lecture:** Zoom (8:10 am – 9:10 am) or Herbst Hall, 1600 Divisadero Street, 2<sup>nd</sup> Floor

**Patient Presentations and Discussion:** Zoom (9:10 am – 10:15 am)

– limited to persons with UCSF appointments

**Moderator:** Sakeen Kashem, M.D., PhD

**Information:** [Chris.Walker@ucsf.edu](mailto:Chris.Walker@ucsf.edu)

UCSF welcomes all participants to our events. If you need a reasonable accommodation to participate in this event because of a disability, please contact Chris Walker at [Chris.Walker@ucsf.edu](mailto:Chris.Walker@ucsf.edu) as soon as possible.

---

**June 04, 2025**

*Grand Rounds and Patient Viewing*

*In-person, Herbst Hall, 1600 Divisadero Street, 2<sup>nd</sup>  
Floor, Hospital Side*

## **BTK and B Cells in Hidradenitis Suppurativa: Pathogenic Roles and Therapeutic Rationale for Targeted Inhibition**

Anubhav N. Mathur M.D., PhD, Pediatric Dermatology, UCSF School of Medicine

### **Objectives:**

1. Review the current understanding of HS pathophysiology
  2. Review the biological function of Bruton's Tyrosine Kinase (BTK) and its role in B cell signaling
  3. Review the evidence supporting B cell and BTK involvement in HS
- 

**June 11, 2025**

*Grand Rounds and Patient Viewing*

*ZOOM*

## **Resident and Fellow Expert Talks**

### **Evolving Role of Incretin Mimetics in Dermatology**

Eduardo Torre, M.D., PhD, PGY-4 Dermatology  
Resident, UCSF

### **Objectives:**

1. Understanding the mechanisms and approved uses of incretin mimetics
2. Explore ongoing and potential dermatologic applications
3. Identify key considerations for clinical

### **Alpelisib for Vascular Anomalies and Overgrowth Syndromes**

Deeti Pithadia, M.D., Pediatric Dermatology Fellow, UCSF

### **Objectives:**

1. Describe the mechanisms of action of alpelisib
2. Recognize that alpelisib therapy may benefit patients with a diverse range of genotypes and phenotypes related to vascular anomalies and overgrowth

3. Understand potential risks and considerations of apelsib treatment in patients of varying ages and comorbidities

### **VEXAS syndrome – A Practical Review**

Lowell Nicholson, M.D., Complex Dermatology  
Fellow, UCSF

#### **Objectives:**

1. Describe the basic pathophysiology of VEXAS syndrome
2. Recognize the key clinical features
3. Review appropriate diagnostic tests
4. Discuss treatment options

---

**June 18, 2025**

*Grand Rounds and Patient Viewing*  
**ZOOM**

#### **MSDO Fellow Talks:**

### **Clinical Considerations in the Management of Locally Advanced Basal Cell Carcinoma in a Patient with Basal Cell Nevus Syndrome**

Shannon Zullo, M.D., Micrographic Surgery & Dermatologic Oncology Fellow, UCSF

#### **Objectives:**

1. Considerations in the management of advanced basal cell carcinoma with perineural, perivascular, and parotid involvement for the dermatologic surgeon.
2. How do we approach these strategies in a patient with BCNS?
3. Further considerations in long-term management

### **Mohs Meets Quality Improvement: How Surgical Dermatology Can Lead in Value-Based Care**

Fiatsogbe Dzuali, M.D., Micrographic Surgery & Dermatologic Oncology Fellow, UCSF

#### **Objectives:**

1. Define the six core domains of healthcare quality and describe how they apply to procedural dermatology and Mohs surgery.
2. Explain the IHI Model for Improvement and demonstrate how the Plan-Do-Study-Act cycle can be used to implement effective QI initiatives in a Mohs surgery setting.
3. Evaluate real-world quality improvement projects in Mohs surgery across different quality domains.

### **Creating the Perfecting Scar: Early Interventions After Surgery**

Cory Kosche, MD, Micrographic Surgery & Dermatologic Oncology Fellow, UCSF

#### **Objectives:**

1. Discuss the natural course of wound healing after surgery and factors that contribute to unsatisfactory surgical scars
  2. Review best practices and evidence for aftercare following surgery
  3. Compare treatment modalities for early intervention in surgical scars including injectable medications and energy based devices.
-

**June 25, 2025**  
**Grand Rounds**  
**Patient Viewing CANCELLED**  
***In-person, Herbst Hall, 1600 Divisadero Street, 2<sup>nd</sup>***  
***Floor, Hospital Side***  
***Refreshments to Follow in The Healing Garden at***  
***Women's Health Center***

**Dermatologic Surgery- “Pearls I Learned from Roy”**

Sungat K. Grewal, M.D., FAAD, Co-Director, Laser Surgery and Aesthetic Medicine Dermatology, UCSF  
Isaac Neuhaus, M.D., Dermatologic Surgery, UCSF  
Drew Saylor M.D., MPH., Dermatologic Surgery, UCSF  
Daniel Klufas M.D., Dermatologic Surgery, UCSF  
Siegrid Yu M.D., Dermatologic Surgery, UCSF

---

**Accreditations: YOU MUST SIGN IN TO QUALIFY FOR CME CREDIT.**

In support of improving patient care, UCSF Office of CME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

University of California, San Francisco, designates this live activity for a maximum of 40 AMA PRA Category 1 credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity. No more than 2 credits may be claimed for each 2-hour session.

Speaker Disclosures: Anubhav N. Mathur, M.D., PhD, has disclosed that he has an industry sponsored research agreement with Novartis.

Eduardo Torre, M.D., PhD, Lowell Nicholson, M.D., and Deeti Pithadia, M.D. have stated they have no relationships to disclose.

Shannon Zullo, M.D, Fiatsogbe Dzuali M.D., and Cory Kosche, M.D. have stated they have no relationships to disclose.

Moderator Disclosures: Sakeen Kashem, M.D., PhD has stated he has no financial relationships to disclose.

Planner Disclosures: Hunter Shain, PhD has disclosed that he has an industry sponsored research agreement with Kenview. Kelly Cordoro, MD and Amanda Twigg, MD have stated they have no relationships to disclose.